Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis

Overview of attention for article published in Degenerative Neurological and Neuromuscular Disease, May 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

news: 3 news outlets
twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 70 Dimensions

Readers on

mendeley: 154 Mendeley

Summary News X Facebook Dimensions citations

So far, Dimensions has found 70 publications that cite this research output.

70

The most recent citing publications are shown below. View all 70 publications that cite this research output on Dimensions.

Glycolic acid and D-lactate—putative products of DJ-1—restore neurodegeneration in FUS - and SOD1-ALS

Article in Life Science Alliance (May 2024)

Continuity of treatment in ALS: Benefits and challenges of maintaining riluzole over the course of the disease

Article in Journal of the Neurological Sciences (May 2024)

Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade

Article in International Journal of Molecular Sciences (April 2024)